Number of chemical drug applications with technical reviews approved in China 2021
In 2021, the Chinese Center for Drug Evaluation of the National Medical Products Administration (NMPA) approved more than 5,500 chemical drug evaluation applications that were subjected to technical reviews. The approvals included 1,310 Investigational New Drug (IND) applications, more than 1,000 therapeutic effect consistency assessment requests, and 160 New Drug Applications (NDA). The number of Abbreviated New Drug Applications (ANDA) also exceeded 1,000. An ANDA application is a drug approval application submitted to the regulatory body for the general approval and sale of a generic drug product.